FDA Brief

Warning letters Food

FDA warning letter to

3RD Day Nutraceuticals, LLC

LowIssued Jul 8, 2021Posted Aug 10, 2021Office of Human and Animal Food Operations East – Division 1

FDA says 3rd Day Nutraceuticals marketed four supplements as unapproved drugs with disease claims on its website.

What happened

FDA reviewed the company’s website at https://3rddaynutra.com/ in April 2021 and found it took orders for Immune Booster, Allergy Support, Inflammatory Response Support, and Revive & Recover. FDA said website claims established the products were intended to cure, mitigate, treat, or prevent disease. FDA concluded the products are unapproved new drugs and misbranded because they lack adequate directions for use.

What FDA found

  1. Website claims stated the four products were intended to cure, mitigate, treat, or prevent disease, making them drugs.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs—meaning they are sold for disease uses without FDA approval—because they are not generally recognized as safe and effective for those uses.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for use for conditions that are not amenable to self-diagnosis or treatment without a licensed practitioner.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, including how it will prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, the company must explain the delay and state when it will finish.

Who should pay attention

  • dietary supplement brands making disease-treatment claims
  • companies selling immunity or allergy supplements online
  • retailers and distributors carrying supplements with drug-like claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk